AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8284627 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (tetracycline 2 g, metronidazole 750 mg, bismuth subsalicylate 5 or 8 tablets) plus ranitidine 300 mg
Number of subjects: 31
Study 8284627 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine alone 300 mg
Number of subjects: 31
Study 3542360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet light activated resin with a filler
Number of subjects: 1766
Study 3542360 — intervention group
Group type: COMPARATOR
Intervention: Autopolymerizing resin without a filler
Number of subjects: 1766
Study 3542360 — intervention group
Group type: EXPERIMENTAL
Intervention: Carious teeth
Number of subjects: 1766
Study 3542360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound teeth
Number of subjects: 1766
Study 3542360 — intervention group
Group type: EXPERIMENTAL
Intervention: Premolars
Number of subjects: 1766
Study 3542360 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary premolars
Number of subjects: 1766
Study 3542360 — intervention group
Group type: EXPERIMENTAL
Intervention: Resealed teeth after 1 year
Number of subjects: 1766
Study 29458317 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 kcal/mL enteral nutrition formulation
Number of subjects: 4000
Study 29458317 — intervention group
Group type: COMPARATOR
Intervention: 1 kcal/mL enteral nutrition formulation
Number of subjects: 4000
Study 27316705 — intervention group
Group type: EXPERIMENTAL
Intervention: iBeST (online training)
Number of subjects: 35
Study 27316705 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face workshop (control group)
Number of subjects: 35
Study 25749601 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength After Breast Cancer exercise intervention
Number of subjects: 84
Study 22221566 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed polyglyconate suture (V-Loc 180; Covidien)
Number of subjects: 70
Study 22221566 — intervention group
Group type: COMPARATOR
Intervention: Standard monofilament suture (4-0 poliglecaprone 25; Monocryl)
Number of subjects: 70
Study 22221566 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed polyglyconate suture
Number of subjects: 70
Study 22221566 — intervention group
Group type: COMPARATOR
Intervention: Standard monofilament suture
Number of subjects: 70
Study 20526196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 79
Study 20526196 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch
Number of subjects: 79
Study 20526196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 79
Study 18842742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral stress management (CBSM) intervention for 10 weeks
Number of subjects: 128
Study 18842742 — intervention group
Group type: COMPARATOR
Intervention: 1-day psychoeducation seminar (Control)
Number of subjects: 128
Study 15838528 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) cycling at resistances of 0, 6.25, and 12.5 Watts (W)
Number of subjects: 6
Study 15838528 — intervention group
Group type: COMPARATOR
Intervention: Cycling without FES at resistances of 0, 60, and 120 W
Number of subjects: 6
Study 12068132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Intervention (DIET group)
Number of subjects: 24
Study 12068132 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + Dietary Intervention (HRT +DIET group)
Number of subjects: 24
Study 10406828 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg/d)
Number of subjects: 22
Study 10406828 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (20 mg/d)
Number of subjects: 22
Study 8926537 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of red pepper
Number of subjects: 0
Study 8926537 — intervention group
Group type: COMPARATOR
Intervention: Control diet (without red pepper)
Number of subjects: 0
Study 8926537 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of red pepper with propranolol
Number of subjects: 0
Study 8926537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1747644 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate 120 mg four times a day for four weeks
Number of subjects: 90
Study 1747644 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg and amoxycillin 500 mg each three times a day for one week
Number of subjects: 90
Study 1747644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subcitrate 120 mg four times a day for four weeks, metronidazole 400 mg three times a day for one week, plus amoxycillin 500 mg three times a day for the first week
Number of subjects: 90
Study 7107086 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironothiazid (50 mg spironolactone, 50 mg hydrochlorothiazide)
Number of subjects: 6
Study 7107086 — intervention group
Group type: COMPARATOR
Intervention: Aldactone dragees (50 mg) plus Esidrex tablets (25 mg)
Number of subjects: 6
Study 30328486 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with patients regarding trial participation factors
Number of subjects: 30
Study 30328486 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with clinicians regarding recruitment factors
Number of subjects: 30
Study 30328486 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 30
Study 30328486 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial retention
Number of subjects: 30
Study 30293332 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3044
Study 30293332 — intervention group
Group type: COMPARATOR
Intervention: Single aspirin
Number of subjects: 3044
Study 26864127 — intervention group
Group type: EXPERIMENTAL
Intervention: D2-biofortified bread (25 µg D2/d)
Number of subjects: 33
Study 26864127 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 supplement (25 µg D2/d)
Number of subjects: 33
Study 26864127 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 supplement (25 µg D3/d)
Number of subjects: 33
Study 26864127 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill and regular bread (0 µg D2 or D3/d)
Number of subjects: 33
Study 24674962 — intervention group
Group type: EXPERIMENTAL
Intervention: Active biofeedback treatment
Number of subjects: 21
Study 24674962 — intervention group
Group type: COMPARATOR
Intervention: Sham feedback (control)
Number of subjects: 21
Study 22587791 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% foam
Number of subjects: 659
Study 22587791 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 659
Study 19492716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-shrinkage resin composite (InTen-S)
Number of subjects: 50
Study 19492716 — intervention group
Group type: COMPARATOR
Intervention: Hybrid resin composite (Point 4)
Number of subjects: 50
Study 17584007 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 4 days prior to hypoxia exposure
Number of subjects: 8
Study 17584007 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 days prior to hypoxia exposure
Number of subjects: 8
Study 15098799 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (240 ml, regular-strength)
Number of subjects: 20
Study 15098799 — intervention group
Group type: COMPARATOR
Intervention: Bottled purified water (control)
Number of subjects: 20
Study 12185799 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in worksite health-promotion program (n = 2596)
Number of subjects: 4189
Study 12185799 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipants (control group)
Number of subjects: 4189
Study 12185799 — intervention group
Group type: EXPERIMENTAL
Intervention: Program participants
Number of subjects: 4189
Study 9474534 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete denture therapy procedures
Number of subjects: 0
Study 9474534 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural research in denture therapy
Number of subjects: 0
Study 7857356 — intervention group
Group type: EXPERIMENTAL
Intervention: pidotimod 400 mg
Number of subjects: 235
Study 7857356 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 235
Study 2509605 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR‐22 alone
Number of subjects: 42
Study 2509605 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR‐22 and UFT (or FT‐207) in combination
Number of subjects: 42
Study 2509605 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR‐22 prophylactically
Number of subjects: 42
Study 2509605 — intervention group
Group type: COMPARATOR
Intervention: MOR‐22 and UFT (or FT‐207)
Number of subjects: 42
Study 145237 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc
Number of subjects: 37
Study 145237 — intervention group
Group type: COMPARATOR
Intervention: Tetracyclines (oxytetracycline)
Number of subjects: 37
Study 31549282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram developed using significant predictors (Primary tumor, Frankel Grade, Karnofsky Performance Score, adjuvant therapy)
Number of subjects: 244
Study 27648629 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Number of subjects: 30
Study 27648629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26280756 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 25, 100, 200, or 400 mg (single dose and repeated doses for 14 days)
Number of subjects: 61
Study 22983502 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange sex (>=1 exchange sex partner, past 90 days) among female NIDUs
Number of subjects: 417
Study 22983502 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening ties that provide social support but not drug support
Number of subjects: 417
Study 22983502 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing ties that provide both drug and social support
Number of subjects: 417
Study 21458015 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized training course for single-port laparoscopic surgery
Number of subjects: 10
Study 21458015 — intervention group
Group type: COMPARATOR
Intervention: Traditional training course for laparoscopy basic skills
Number of subjects: 10
Study 18065204 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln-supplemented PN (Gln-PN)
Number of subjects: 59
Study 18065204 — intervention group
Group type: COMPARATOR
Intervention: Standard PN (Gln-free)
Number of subjects: 59
Study 18065204 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Gln-PN and Standard PN)
Number of subjects: 59
Study 17045558 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-dose regimen of artemether-lumefantrine
Number of subjects: 1368
Study 12938592 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled intravenous morphine
Number of subjects: 80
Study 12938592 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 80
Study 12938592 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs
Number of subjects: 80
Study 12938592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 80
Study 10716474 — intervention group
Group type: COMPARATOR
Intervention: L-arginine (8 g/day)
Number of subjects: 40
Study 10716474 — intervention group
Group type: COMPARATOR
Intervention: Training group (daily handgrip training)
Number of subjects: 40
Study 10716474 — intervention group
Group type: COMPARATOR
Intervention: L-arginine + Training
Number of subjects: 40
Study 10716474 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (inactive)
Number of subjects: 40
Study 9366938 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms.kg-1
Number of subjects: 120
Study 9366938 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg-1
Number of subjects: 120
Study 9366938 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 80 micrograms.kg-1
Number of subjects: 120
Study 9366938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 1490801 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil (200 mg orally, 100 mg intravenously)
Number of subjects: 15
Study 3987781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg) before standardized breakfast (Phase A)
Number of subjects: 10
Study 3987781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg) after standardized breakfast (Phase B)
Number of subjects: 10
Study 30601920 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg twice daily
Number of subjects: 20
Study 30601920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30601920 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 20
Study 28671938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) for hospitalized patients with HFrEF
Number of subjects: 119
Study 28671938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) for stable outpatients with HFrEF
Number of subjects: 119
Study 28671938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) for total cohort
Number of subjects: 119
Study 28671938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) for those who completed CR
Number of subjects: 119
Study 26743070 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force monitoring during catheter ablation
Number of subjects: 28
Study 26743070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contact force monitoring)
Number of subjects: 28
Study 24747978 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 20
Study 24747978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22067765 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CVR)
Number of subjects: 95
Study 22067765 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone
Number of subjects: 95
Study 19643646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants (two 4-hr group sessions)
Number of subjects: 170
Study 19643646 — intervention group
Group type: COMPARATOR
Intervention: Control participants (2-hr session on healthy nutrition)
Number of subjects: 170
Study 18781148 — intervention group
Group type: EXPERIMENTAL
Intervention: Control Preferences Scale (CPS)
Number of subjects: 130
Study 18781148 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician views on patient participation
Number of subjects: 130
Study 18781148 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient views on participation
Number of subjects: 130
Study 18781148 — intervention group
Group type: EXPERIMENTAL
Intervention: General views on participation
Number of subjects: 130
Study 18781148 — intervention group
Group type: EXPERIMENTAL
Intervention: General views on clinician ability
Number of subjects: 130
Study 18781148 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician reluctance
Number of subjects: 130
Study 15631889 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDHHC8 SNP (rs175174)
Number of subjects: 1090
Study 15631889 — intervention group
Group type: COMPARATOR
Intervention: Control group (529 individuals)
Number of subjects: 1090
Study 12357163 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural blockade with local anesthetic and opioid
Number of subjects: 16
Study 12357163 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia with morphine
Number of subjects: 16
Study 10490854 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐dopa
Number of subjects: 13
Study 10490854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9772584 — intervention group
Group type: EXPERIMENTAL
Intervention: Zusanli point immunotherapy (ZPIT)
Number of subjects: 69
Study 9772584 — intervention group
Group type: COMPARATOR
Intervention: Conventional desensitization therapy
Number of subjects: 69
Study 9772584 — intervention group
Group type: COMPARATOR
Intervention: Injected normal saline
Number of subjects: 69
Study 1929138 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term drainage (drain removed after 5 days)
Number of subjects: 84
Study 1929138 — intervention group
Group type: COMPARATOR
Intervention: Standard drainage (drain removed when fluid was less than 20 ml per day)
Number of subjects: 84
Study 1929138 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term drainage
Number of subjects: 84
Study 1929138 — intervention group
Group type: COMPARATOR
Intervention: Standard drainage
Number of subjects: 84
Study 6812337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clebopride 1 mg orally at 24.00 h
Number of subjects: 10
Study 6812337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clebopride 1 mg orally at 09.00 h
Number of subjects: 10
Study 6812337 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 24.00 h
Number of subjects: 10
Study 30763755 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline treatment
Number of subjects: 0
Study 28660720 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone for 3 days
Number of subjects: 79
Study 28660720 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 79
Study 25028414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous baclofen (3 mg and 5 mg)
Number of subjects: 12
Study 25028414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral baclofen (5 mg and 10 mg)
Number of subjects: 12
Study 23872994 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief two-session counselor-delivered computer-tailored intervention
Number of subjects: 120
Study 23872994 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study 20605840 — intervention group
Group type: EXPERIMENTAL
Intervention: Thr/Ser and Ser/Ser genotype
Number of subjects: 1043
Study 20605840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuin-A levels
Number of subjects: 1043
Study 20605840 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation and diabetes
Number of subjects: 1043
Study 19901165 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (3 years)
Number of subjects: 468
Study 19901165 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by interferon beta‐1b (> or = 1 year)
Number of subjects: 468
Study 19901165 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline presence of at least 9 T2-weighted lesions
Number of subjects: 468
Study 19901165 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline presence of at least 3 periventricular lesions
Number of subjects: 468
Study 19901165 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a fixed cutoff of at least 3 Barkhof criteria
Number of subjects: 468
Study 19901165 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissemination in time at 9-month MR imaging
Number of subjects: 468
Study 17020437 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic, controlled-release methylphenidate (OROS MPH)
Number of subjects: 0
Study 17020437 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (IR MPH) dosed three times daily
Number of subjects: 0
Study 17020437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17020437 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stimulant treatments (e.g., atomoxetine)
Number of subjects: 0
Study 14769594 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) once daily
Number of subjects: 30
Study 14769594 — intervention group
Group type: COMPARATOR
Intervention: Timolol (0.5%) twice daily
Number of subjects: 30
Study 11233547 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal injection
Number of subjects: 80
Study 11233547 — intervention group
Group type: COMPARATOR
Intervention: Peritumoural injection
Number of subjects: 80
Study 9000414 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA) 10 micromol/kg
Number of subjects: 16
Study 9000414 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA) 25 micromol/kg
Number of subjects: 16
Study 9000414 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA) 50 micromol/kg
Number of subjects: 16
Study 9000414 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA) 100 micromol/kg
Number of subjects: 16
Study 9000414 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA)
Number of subjects: 16
Study 8130709 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief nurse‐administered anti‐smoking intervention
Number of subjects: 751
Study 8130709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to stop smoking
Number of subjects: 751
Study 8130709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained cessation
Number of subjects: 751
Study 8130709 — intervention group
Group type: EXPERIMENTAL
Intervention: Social variables (e.g., marital status, time spent with smokers)
Number of subjects: 751
Study 3298071 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg, two 400 mg tablets, five times daily for seven days)
Number of subjects: 205
Study 3298071 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo, five times daily for seven days)
Number of subjects: 205
Study 3298071 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 205
Study 3298071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 30922004 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (excellent clinical efficacy)
Number of subjects: 0
Study 30922004 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (good clinical efficacy)
Number of subjects: 0
Study 30922004 — intervention group
Group type: COMPARATOR
Intervention: Group C (poor clinical efficacy)
Number of subjects: 0
Study 28259273 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg orally 2 hours prior to procedure, then 100 mg twice a day for 5 days)
Number of subjects: 131
Study 28259273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral placebo 2 hours prior to procedure, then placebo twice a day for 5 days)
Number of subjects: 131
Study 28259273 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (in subgroup with elevated posttraumatic distress scores)
Number of subjects: 131